. Erratum: Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol 2023 Dec 19:JCO2302629. doi: 10.1200/JCO.23.02629.
PMID: 38113437